Conditions

This post was originally published on this site Minerva Biotechnologies will soon start the first human trials testing its investigational therapy huMNC2-CAR44, a CAR T-cell immunotherapy intended for breast cancer that has spread to other parts of the body. The announcement comes after the U.S. Food and Drug Administration (FDA) approved the company’s investigational new…

This post was originally published on this site A first-in-human Phase 1 clinical trial has been launched to assess the effects of NantKwest’s investigational PD-L1 t-haNK cell therapy in patients with locally advanced or metastatic solid cancers. The authorization to start the trial came after the U.S. Food and Drug Administration (FDA) completed a review…

This post was originally published on this site Nearly $169,000 was raised to support the Leukemia & Lymphoma Society’s research, legislative advocacy, and patient support efforts by one of its chapter’s Man & Woman of the Year campaign. California residents Nancy Whitman and John Romley won the title for the Silicon Valley & Monterey Bay…

This post was originally published on this site Anixa Biosciences, a leading company developing anti-cancer immunotherapies, is partnering with the Cleveland Clinic to advance a vaccine against triple-negative breast cancer (TNBC) to testing in humans. “We are pleased to be able to work with Anixa to advance this technology into human trials,” Cleveland Clinic researcher…

This post was originally published on this site The Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency (EMA), has recommended that Empliciti (elotuzumab) in combination with Pomalyst (pomalidomide) and low-dose dexamethasone be approved to treat adults with relapsed or refractory multiple myeloma in Europe. The therapy, collectively known as the…

This post was originally published on this site Women with ovarian cancer who have a family history of breast or ovarian cancer, and are younger than 45 if breast cancer in a near relative makes up that history, are more likely to have inherited BRCA mutations and could benefit from a genetic test to see if they…

This post was originally published on this site Men with prostate cancer who undergo treatment with androgen deprivation therapy (ADT) — a form of hormone therapy that aims to slow disease progression by reducing the levels of male hormones — may be more likely to develop Alzheimer’s disease and dementia, a large database study reports.…

This post was originally published on this site Melanoma patients who become resistant to immune checkpoint inhibitors may regain susceptibility to such treatments after receiving Targovax‘s immune activator ONCOS-102, early clinical trial findings suggest. The trial is testing a combination of ONCOS-102 and the immune checkpoint inhibitor Keytruda (pembrolizumab) in advanced or surgery-ineligible melanoma patients…

This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved Pfizer’s Ruxience (rituximab-pvvr), a biosimilar to Rituxan (rituximab), for all non-Hodgkin’s lymphoma indications of its reference product, the company announced. The therapy was also approved for people with chronic lymphocytic leukemia (CLL), as well as granulomatosis with polyangiitis (GPA)…

This post was originally published on this site A new report describes a woman with a very rare case of sarcoidosis involving only the spine who entered full remission after surgical removal of the lesion followed by treatment with corticosteroids. Based on this case report, researchers advised that cases of spinal sarcoidosis should be managed…